Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

Oncotarget

Volumn 6, Issue 25, 2015, Pages 21547-21556

  Ning, Shoucheng ^a   Sekar, Thillai Veerapazham ^b   Scicinski, Jan ^c   Oronsky, Bryan ^c   Peehl, Donna M ^a   Knox, Susan J ^a   Paulmurugan, Ramasamy ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EpicentRx   (United States)

Author keywords

ARE; Biomarker; Cancer; Nrf2; Oxidative stress

Indexed keywords

ANTINEOPLASTIC AGENT; FIREFLY LUCIFERASE; HEME OXYGENASE 1; NADPH DEHYDROGENASE QUINONE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; RENILLA LUCIFERIN 2 MONOOXYGENASE; RRX 001; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; HMOX1 PROTEIN, MOUSE; LUCIFERASE; MEMBRANE PROTEIN; NFE2L2 PROTEIN, MOUSE; NITRO DERIVATIVE; NQO1 PROTEIN, MOUSE; PHOTOPROTEIN; RED FLUORESCENT PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RRX-001; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOSE TIME EFFECT RELATION; DRUG RESPONSE; DRUG SENSITIVITY; GENE ACTIVATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; LUMINESCENCE; MALE; METABOLISM; NUDE MOUSE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZETIDINES; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HEME OXYGENASE-1; LUCIFERASES; LUMINESCENCE; LUMINESCENT PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM TRANSPLANTATION; NF-E2-RELATED FACTOR 2; NITRO COMPOUNDS; OXIDATIVE STRESS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84940758684     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4249     Document Type: Article

References (32)

1. Mitsuishi Y, Motohashi H, Yamamoto M. The Keap1-Nrf2 system in cancer: Stress response and anabolic metabolism. Front Oncol. 2012; 2:200.
2. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal. 2010; 13:1665-78.
3. Bloom DA, Jaiswal AK. Phosphorylation of Nrf2 at Ser(40) by pro-tein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinine oxidoreductase-1 gene expression. J Biol Chem. 2003; 278:44675-82.
4. Huang F, Nie C, Yang Y, Yue W, Ren Y, Shang Y, Wang X, Jin H, Xu C, Chen Q. Selenite induces redox-dependent Bax activation and apoptosis in colorectal cancer cells. Free Radic Biol Med. 2009; 46:1186-96.
5. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014; 39:199-218.
6. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol. 2003; 43:233-60.
7. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res. 2008; 58:262-70.
8. Bednarski MD, Knox SJ, Cannizzo L, Warner K, Wardle R, Velarde S, Ning S. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof. United States patent US7507842B2, 2009.
9. Straessler NA, Cannizzo LF, Li P, Kramer MP, Rosellberg DM. Methods of synthesizing and isolating N-(bromoacetyl)-3'3-dinitroazetidine and a composition including the same. United States patent US8471041B2, 2013.
10. Straessler NA, Lesley MW, Cannizzo LF. Development of a Safe and Efficient Two-Step Synthesis for Preparing 1-Bromoacetyl-3, 3-dinitroazetidine, a Novel Clinical Anticancer Candidate. Org Process Res Dev. 2012; 16:512-7.
11. Ning S, Bednarski MD, Oronsky B, Scicinski J, Saul G, Knox SJ. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012; 72:2600-8.
12. Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, Marini J, Adams CM, Fitch WL. Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab Dispos. 2012; 40:1810-6.
13. Oronsky B, Oronsky N, Knox SJ, Fanger G, Scicinski J. Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment. Anticancer Agents Med Chem. 2014; 14:1121-7.
14. Reid T, Dad S, Korn R, Oronsky B, Knox SJ, Scicinski J. Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients. Case Rep Oncol. 2014; 7:79-85.
15. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, Zhang D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008; 29:1235-43.
16. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, Zhang DD. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010; 70:5486-96.
17. McDonald JY, Kim K, Norris AJ, Vlashi E, Phillips TM, Lagadec C, Della Donna L, Ratikan J, Szelag H, Hlatky L, McBride WH. Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res. 2010; 70:8886-95.
18. Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012; 32:687-726.
19. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24:7130-9.
20. Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jawarski T, Tobon-Velasco JC, Devijver H, Garcia-mayoral MF, Van Leuven F, Hayes JD, Bertho G, Cuadrado A. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol Cell Biol. 2012; 32:3486-99.
21. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, Zhang DD. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009; 34:663-73.
22. Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, Bouwman P, Cescon DW, Elia AJ, Winterton-Perks Z, Cruickshank J, Brenner D, Tseng A, Musgrave M, Berman HK, Khokha R, Jonkers J, Mak TW, Gauthier ML. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med. 2013; 210:1529-44.
23. Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, Mak TW. Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proc Natl Acad Sci USA. 2014; 111:4472-7.
24. Gan L, Johnson DA, Johnson JA. Keap1-Nrf2 activation in the presence and absence of DJ-1. Eur J Neurosci. 2010; 31:967-77.
25. Jiang ZY, Chu HX, Xi MY, Yang TT, Jia JM, Huang JJ, Guo XK, Zhang XJ, You QD, Sun HP. Insight into the intermolecular recognition mechanism between Keap1 and IKKβ combining homology modelling, protein-protein docking, molecular dynamics simulations and virtual alanine mutation. PloS One. 2013; 8:e75076.
26. Kovac S, Angelova PR, Holmstrom KM, Dinkova-Kostova AT, Abramov AY. Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys Acta. 2014; 850:794-801.
27. Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, Babaei-Jadidi R, Thornalley PJ. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes. 2008; 57:2809-17.
28. Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, Kwak MK, Jung Y. Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. Eur J Pharmacol. 2010; 643:21-8.
29. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA. 2005; 102:4584-9.
30. Wen Z, Wang Z, Wang S, Ravula R, Yang L, Xu J, Wang C, Zuo Z, Chow MS, Shi L, Huang Y. Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. PloS One. 2011; 6:e18278.
31. Hu Q, Zhang DD, Wang L, Lou H, Ren D. Eriodictyol-7-O-glucoside, a novel Nrf2 activator, confers protection against cisplatin-induced toxicity. Food Chem Toxicol. 2012; 50:1927-32.
32. Fu KK, Lam KN, Rayner PA. The influence of time sequence of cisplatin administration and continuous low dose rate irradiation (CLDRI) on their combined effects on a murine squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 1985; 11:2119-24.